Association of fall risk-increasing drugs with falls in generally healthy older adults: a 3-year prospective observational study of the DO-HEALTH trial. de Godoi Rezende Costa Molino C, et al, BMC Geriatr 2024.

  • Proposé le : 07/08/2025 04:07:11
  • Par : Bot
  • Avec la version du site : v2021_01_12
  • Revu par :
    • Mettre votre nom d'utilisateur
    • Mettre votre nom d'utilisateur
Notes sur les tags :
  • Adopter cette revue :
    Si vous souhaitez prendre en charge cette revue d'article, merci de remplacer le tag Non_attribué par Attribué et ajoutez aussi votre nom d'utilisateur à l'emplacement prévu.
  • Réaliser des modifications :
    Pour modifier ce document, il est nécessaire d'être connecté au site. Pour cela, assurez-vous d'avoir des identifiants valides. Si vous n'en avez pas, contactez-nous. Pour vous connecter, cliquez sur l'icône dans la barre de navigation.
  • Demander la finalisation de la revue de l'article :
    Une fois revue et complétée, merci de remplacer l'étiquette Non_finalisé par A_finaliser. Un administrateur se chargera de valider la revue et de la publier avec le tag Finalisé.

Background: The association between fall risk-increasing drugs (FRIDs, medications known to be associated with falls) and the number of falls among generally healthy and active community-dwelling older adults is understudied. Prior studies have focused on individual medication classes or have predominantly relied on retrospective assessments of falls. The aim of this study was to investigate the association between FRID use at baseline and the prospective incidence rates of total, injurious and recurrent falls in community-dwelling older adults.

Methods: This is a 3-year observational analysis of DO-HEALTH, a randomized controlled trial, among community-dwelling adults aged ≥ 70 years without major diseases at baseline. The main exposures were use of at least one FRID and multiple FRIDs (≥ 2 FRIDs) at baseline. The number of total falls (including high- and low-trauma falls, as well as injurious falls) over 3 years of follow-up was defined as the primary outcome, and the number of injurious and the number of recurrent total falls (≥ 2 falls), as the two separate secondary outcomes. To examine these associations, separate negative binomial regression models controlled for the fixed effects of treatment allocation in the DO-HEALTH trial, study site, fall in the last year, age, sex, BMI, and walking aid were used. Additionally, an offset of the logarithm of each participant's time in the study was included in the models.

Results: A total of 2157 participants were included, with a baseline median age of 74.0 years, 61.7% of whom were women, and 41.9% having experienced a prior fall in the year preceding enrolment. At baseline, 908 (42.1%) participants used at least one FRID, and 351 (16.3%) reported multiple FRIDs use. Prospectively, over 3 years of follow-up, 3333 falls were reported by 1311 (60.8%) out of the 2157 participants. Baseline use of at least one FRID was significantly associated with increased incidence rates of total falls (incidence rate ratio (IRR) [95% Confidence Interval (CI)] = 1.13 [1.01-1.27]), injurious falls (IRR = 1.15 [1.02-1.29]), and recurrent falls (IRR = 1.12 [1.01-1.23]) over 3 years. These associations were most pronounced among users of multiple FRIDs, with increased incidence rates of total falls (IRR = 1.22 [1.05-1.42]), injurious falls (IRR = 1.33 [1.14-1.54]) and recurrent falls (IRR = 1.14 [1.02-1.29]).

Conclusion: Our results suggest that FRID use is associated with increased prospective incidence rates of total, injurious, and recurrent falls even among generally healthy older adults.

Trial registration: DO-HEALTH is registered as NCT01745263 on clinicaltrials.gov, with a registration date of 2012-12-06.

Références de l'article


Discussion

  • Cette section peut être éditée par les relecteurs, les rédacteurs, les modérateurs et les administrateurs. Elle regroupe l'ensemble des échanges autours de la référence ci-dessus présentée.
  • Référez-vous à cette page pour connaître le rôle des utilisateurs et pour participer à la discussion.
  • Il n'y a, pour l'instant, aucune discussion en cours.

Éditer la discussion



Gardez le contact

Suivez notre utilisateur Twitter : @AgingPapers
Nos rencontres visio